AMNEAL PHARMACEUTICALS INC (AMRX) Stock News
NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD
AMRX Latest News, Press Relases and Analysis
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12,...
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
3 Reasons Growth Investors Will Love Amneal (AMRX)
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock?
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory
The observance of black spots was reported in a product quality complaint, the U.S. FDA said, while noting that oral products contaminated with Aspergillus may result in serious and life-threatening infections.
Amneal to Participate at Upcoming Investor Conferences in June
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences:...
Amneal to Participate at Upcoming Investor Conferences in June
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches.
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form ...
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
Amneal (AMRX) delivered earnings and revenue surprises of 40% and 2.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VRCA
Amneal Reports First Quarter 2025 Financial Results
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth?
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Amneal to Report First Quarter 2025 Results on May 2, 2025
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
